Cargando…

The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study

BACKGROUND: Hepatic failure has been associated with reported therapeutic use of acetaminophen by alcoholic patients. The highest risk period for alcoholic patients is immediately after discontinuation of alcohol intake. This period exhibits the largest increase in CYP2E1 induction and lowest glutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuffner, EK, Green, JL, Bogdan, GM, Knox, PC, Palmer, RB, Heard, K, Slattery, JT, Dart, RC
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894983/
https://www.ncbi.nlm.nih.gov/pubmed/17537264
http://dx.doi.org/10.1186/1741-7015-5-13
_version_ 1782133901943111680
author Kuffner, EK
Green, JL
Bogdan, GM
Knox, PC
Palmer, RB
Heard, K
Slattery, JT
Dart, RC
author_facet Kuffner, EK
Green, JL
Bogdan, GM
Knox, PC
Palmer, RB
Heard, K
Slattery, JT
Dart, RC
author_sort Kuffner, EK
collection PubMed
description BACKGROUND: Hepatic failure has been associated with reported therapeutic use of acetaminophen by alcoholic patients. The highest risk period for alcoholic patients is immediately after discontinuation of alcohol intake. This period exhibits the largest increase in CYP2E1 induction and lowest glutathione levels. Our hypothesis was that common liver tests would be unaffected by administration of the maximum recommended daily dosage of acetaminophen for 3 consecutive days to newly-abstinent alcoholic subjects. METHODS: Adult alcoholic subjects entering two alcohol detoxification centers were enrolled in a prospective double-blind, randomized, placebo-controlled trial. Subjects were randomized to acetaminophen, 4 g/day, or placebo for 3 consecutive days. The study had 95% probability of detecting a 15 IU/L difference in serum ALT. RESULTS: A total of 443 subjects were enrolled: 308 (258 completed) received acetaminophen and 135 subjects (114 completed) received placebo. Study groups did not differ in demographics, alcohol consumption, nutritional status or baseline laboratory assessments. The peak mean ALT activity was 57 ± 45 IU/L and 55 ± 48 IU/L in the acetaminophen and placebo groups, respectively. Subgroup analyses for subjects presenting with an elevated ALT, subjects fulfilling a diagnosis of alcoholic hepatitis and subjects attaining a peak ALT greater than 200 IU/L showed no statistical difference between the acetaminophen and control groups. The one participant developing an increased international normalized ratio was in the placebo group. CONCLUSION: Alcoholic patients treated with the maximum recommended daily dose of acetaminophen for 3 consecutive days did not develop increases in serum transaminase or other measures of liver injury. Treatment of pain or fever for 3 days with acetaminophen appears safe in newly-abstinent alcoholic patients, such as those presenting for acute medical care.
format Text
id pubmed-1894983
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18949832007-06-21 The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study Kuffner, EK Green, JL Bogdan, GM Knox, PC Palmer, RB Heard, K Slattery, JT Dart, RC BMC Med Research Article BACKGROUND: Hepatic failure has been associated with reported therapeutic use of acetaminophen by alcoholic patients. The highest risk period for alcoholic patients is immediately after discontinuation of alcohol intake. This period exhibits the largest increase in CYP2E1 induction and lowest glutathione levels. Our hypothesis was that common liver tests would be unaffected by administration of the maximum recommended daily dosage of acetaminophen for 3 consecutive days to newly-abstinent alcoholic subjects. METHODS: Adult alcoholic subjects entering two alcohol detoxification centers were enrolled in a prospective double-blind, randomized, placebo-controlled trial. Subjects were randomized to acetaminophen, 4 g/day, or placebo for 3 consecutive days. The study had 95% probability of detecting a 15 IU/L difference in serum ALT. RESULTS: A total of 443 subjects were enrolled: 308 (258 completed) received acetaminophen and 135 subjects (114 completed) received placebo. Study groups did not differ in demographics, alcohol consumption, nutritional status or baseline laboratory assessments. The peak mean ALT activity was 57 ± 45 IU/L and 55 ± 48 IU/L in the acetaminophen and placebo groups, respectively. Subgroup analyses for subjects presenting with an elevated ALT, subjects fulfilling a diagnosis of alcoholic hepatitis and subjects attaining a peak ALT greater than 200 IU/L showed no statistical difference between the acetaminophen and control groups. The one participant developing an increased international normalized ratio was in the placebo group. CONCLUSION: Alcoholic patients treated with the maximum recommended daily dose of acetaminophen for 3 consecutive days did not develop increases in serum transaminase or other measures of liver injury. Treatment of pain or fever for 3 days with acetaminophen appears safe in newly-abstinent alcoholic patients, such as those presenting for acute medical care. BioMed Central 2007-05-30 /pmc/articles/PMC1894983/ /pubmed/17537264 http://dx.doi.org/10.1186/1741-7015-5-13 Text en Copyright © 2007 Kuffner et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kuffner, EK
Green, JL
Bogdan, GM
Knox, PC
Palmer, RB
Heard, K
Slattery, JT
Dart, RC
The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study
title The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study
title_full The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study
title_fullStr The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study
title_full_unstemmed The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study
title_short The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study
title_sort effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1894983/
https://www.ncbi.nlm.nih.gov/pubmed/17537264
http://dx.doi.org/10.1186/1741-7015-5-13
work_keys_str_mv AT kuffnerek theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT greenjl theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT bogdangm theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT knoxpc theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT palmerrb theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT heardk theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT slatteryjt theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT dartrc theeffectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT kuffnerek effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT greenjl effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT bogdangm effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT knoxpc effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT palmerrb effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT heardk effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT slatteryjt effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy
AT dartrc effectofacetaminophenfourgramsadayforthreeconsecutivedaysonhepatictestsinalcoholicpatientsamulticenterrandomizedstudy